These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 8763692

  • 1. [Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].
    Gleave M, Santo N, Rennie PS, Goldenberg SL, Bruchovsky N, Sullivan LD.
    Prog Urol; 1996 Jun; 6(3):375-85. PubMed ID: 8763692
    [Abstract] [Full Text] [Related]

  • 2. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW.
    Cancer Res; 1992 Mar 15; 52(6):1598-605. PubMed ID: 1371718
    [Abstract] [Full Text] [Related]

  • 3. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
    Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L.
    J Cell Biochem; 1998 Jun 01; 69(3):271-81. PubMed ID: 9581866
    [Abstract] [Full Text] [Related]

  • 4. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.
    Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD.
    J Steroid Biochem Mol Biol; 1996 May 01; 58(2):139-46. PubMed ID: 8809195
    [Abstract] [Full Text] [Related]

  • 5. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J.
    Clin Cancer Res; 1999 Oct 01; 5(10):2891-8. PubMed ID: 10537358
    [Abstract] [Full Text] [Related]

  • 6. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
    Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD.
    Cancer Res; 1997 Apr 15; 57(8):1584-9. PubMed ID: 9108464
    [Abstract] [Full Text] [Related]

  • 7. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z, Schally AV, Plonowski A, Czompoly T, Csernus B, Varga JL.
    Prostate; 2001 Aug 01; 48(3):188-99. PubMed ID: 11494334
    [Abstract] [Full Text] [Related]

  • 8. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ.
    Eur Urol; 1999 Aug 01; 35 Suppl 1():32-6. PubMed ID: 10081701
    [Abstract] [Full Text] [Related]

  • 9. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
    Cheng L, Zhang S, Sweeney CJ, Kao C, Gardner TA, Eble JN.
    Anticancer Res; 2004 Aug 01; 24(4):2135-40. PubMed ID: 15330153
    [Abstract] [Full Text] [Related]

  • 10. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.
    Miyake H, Hara S, Arakawa S, Kamidono S, Hara I.
    Br J Cancer; 2001 Mar 23; 84(6):859-63. PubMed ID: 11259104
    [Abstract] [Full Text] [Related]

  • 11. The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancer.
    Chang GT, Jhamai M, van Weerden WM, Jenster G, Brinkmann AO.
    Endocr Relat Cancer; 2004 Dec 23; 11(4):815-22. PubMed ID: 15613454
    [Abstract] [Full Text] [Related]

  • 12. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M.
    Cancer Res; 2005 Dec 01; 65(23):11083-93. PubMed ID: 16322258
    [Abstract] [Full Text] [Related]

  • 13. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
    Pether M, Goldenberg SL, Bhagirath K, Gleave M.
    Can J Urol; 2003 Apr 01; 10(2):1809-14. PubMed ID: 12773232
    [Abstract] [Full Text] [Related]

  • 14. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.
    Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME.
    Cancer Res; 2003 Jul 01; 63(13):3575-84. PubMed ID: 12839944
    [Abstract] [Full Text] [Related]

  • 15. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC.
    Cancer Res; 2008 Aug 01; 68(15):6407-15. PubMed ID: 18676866
    [Abstract] [Full Text] [Related]

  • 16. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD, Gleave ME.
    Cancer Res; 2000 Oct 15; 60(20):5825-31. PubMed ID: 11059779
    [Abstract] [Full Text] [Related]

  • 17. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC.
    Prostate; 2006 Jul 01; 66(10):1070-5. PubMed ID: 16637076
    [Abstract] [Full Text] [Related]

  • 18. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ.
    Cancer Res; 2004 Aug 01; 64(15):5489-95. PubMed ID: 15289359
    [Abstract] [Full Text] [Related]

  • 19. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.
    Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG.
    Cancer Res; 1996 Jul 01; 56(13):3042-6. PubMed ID: 8674060
    [Abstract] [Full Text] [Related]

  • 20. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
    Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM.
    Cancer Res; 2000 Aug 01; 60(15):4146-51. PubMed ID: 10945622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.